Chids Mahadevan - 02 Aug 2022 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role
Title: Senior Vice President of Finance (Interim Principal Financial Officer)
Signature
/s/ Shoshana Shendelman, as attorney-in-fact
Issuer symbol
APLT
Transactions as of
02 Aug 2022
Net transactions value
$0
Form type
4
Filing time
04 Aug 2022, 20:38:14 UTC
Previous filing
18 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -19,058 -100% 0 02 Aug 2022 Common Stock 19,058 $2.02 Direct F1, F2
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +19,058 19,058 02 Aug 2022 Common Stock 19,058 $1.05 Direct F1, F2
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -7,264 -100% 0 02 Aug 2022 Common Stock 7,264 $17.05 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +7,264 7,264 02 Aug 2022 Common Stock 7,264 $1.05 Direct F1, F3
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer -8,824 -100% 0 02 Aug 2022 Common Stock 8,824 $49.60 Direct F1, F4
transaction APLT Employee Stock Option (Right to Buy) Disposed to Issuer +8,824 8,824 02 Aug 2022 Common Stock 8,824 $1.05 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.
F2 Reflects an initial grant of 19,058 Options granted on April 13, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on April 13, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
F3 Reflects an initial grant of 13,412 Options granted on May 10, 2021 that vests as follows: One-fourth (1/4th) of the shares subject to the Option were vested upon grant and the remainder of the shares subject to the Option shall vest thereafter in equal monthly installments over the three-year period following the date of grant, subject to the Reporting Person continuing to provide services through each such date.
F4 Reflects an initial grant of 14,606 Options granted on January 29, 2020 that vests as follows: One-fourth (1/4) of the shares subject to the Option shall vest on January 30, 2021, and one thirty-sixth (1/36) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

Title: Senior Vice President of Finance (Interim Principal Financial Officer)